Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?

References

• Dengel LT, Van Zee KJ, King TA, et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol. 2014;21:22–27.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28:1700–1712.
   PubMed Web of Science ®Google Scholar
• Diessner J, Wischnewsky M, Blettner M, et al. Do patients with luminal A breast cancer profit from adjuvant systemic therapy? A retrospective multicenter study. PLoS One. 2016;11:e0168730.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Jensen MB, Burugu S, et al. High-risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial. Clin Cancer Res. 2017;23:946–953.
   PubMed Web of Science ®Google Scholar
• Uchida N, Suda T, Ishiguro K. Effect of chemotherapy for luminal a breast cancer. Yonago Acta Med. 2013;56:51–56.
   PubMed Web of Science ®Google Scholar
• Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet. 2004;364:858–868.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–1144.
   PubMed Web of Science ®Google Scholar
• International Breast Cancer Study, G., Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2002;94:1054–1065.
   PubMedGoogle Scholar
• Noda S, Onoda N, Asano Y, et al. Predictive factors for the occurrence of four or more axillary lymph node metastases in ER-positive and HER2-negative breast cancer patients with positive sentinel node: a retrospective cohort study. Int J Surg. 2016;26:1–5.
   PubMed Web of Science ®Google Scholar
• Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52:1551–1557.
   PubMed Web of Science ®Google Scholar
• Jatoi I, Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17:2334–2340.
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:2055–2063.
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group; Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444.
   PubMed Web of Science ®Google Scholar
• Goldvaser H, Majeed H, Ribnikar D, et al. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. Breast Cancer Res Treat. 2018;169(3):413–425.
   PubMed Web of Science ®Google Scholar
• Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: a brief summary of the consensus discussion. Breast Care (Basel). 2015;10:124–130.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–2223.
   PubMed Web of Science ®Google Scholar
• Maisonneuve P, Disalvatore D, Rotmensz N, et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014;16:R65.
   PubMed Web of Science ®Google Scholar
• Ehinger A, Malmstrom P, Bendahl PO, et al. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol. 2017;56:68–74.
   PubMed Web of Science ®Google Scholar
• Regionala cancercentrum i samverkan. Swedish National Guidelines for Breast cancer. 2018 [cited 2018 May]; Available at: https://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/vardprogram/gallande-vardprogram/
   Google Scholar
• Nieweg OE, Jansen L, Valdes Olmos RA, et al. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med. 1999;26:S11–S16.
   PubMedGoogle Scholar
• Pesek S, Ashikaga T, Krag LE, et al. The false-negative rate of sentinel node biopsy in patients with breast cancer: A meta-analysis. World J Surg. 2012;36:2239–2251.
   PubMed Web of Science ®Google Scholar
• van der Ploeg IM, Nieweg OE, van Rijk MC, et al. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–1284.
   PubMed Web of Science ®Google Scholar
• Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003;98:2307–2315.
   PubMed Web of Science ®Google Scholar
• Durak MG, Akansu B, Akin MM, et al. Factors predicting non-sentinel lymph node involvement in sentinel node positive breast carcinoma. Turk Patoloji Derg. 2011;27:189–195.
   PubMedGoogle Scholar
• Ozmen V, Karanlik H, Cabioglu N, et al. Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat. 2006;95:1–6.
   PubMed Web of Science ®Google Scholar
• Goyal A, Douglas-Jones A, Newcombe RG, et al. Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer. 2004;40:1731–1737.
   PubMed Web of Science ®Google Scholar
• Hung WK, Chan MC, Mak KL, et al. Non-sentinel lymph node metastases in breast cancer patients with metastatic sentinel nodes. ANZ J Surg. 2005;75:27–31.
   PubMed Web of Science ®Google Scholar
• Ban EJ, Lee JS, Koo JS, et al. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer. 2011;14:296–300.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–121.
   PubMed Web of Science ®Google Scholar